

Business Press Release

For Immediate Release

RELEASE DATE
16 August 2022

PharmaLex expands Nordic footprint across key business units with DRA Consulting merger

Alliance strengthens long-held collaboration and builds on overall regulatory, quality and market access services while advancing digital expertise

Frankfurt, Germany – 16 August 2022: [PharmaLex Group](#), a leading provider of specialized services for the pharma, biotech and MedTech industries worldwide, has announced a merger with Finnish consulting company, [DRA Consulting](#).

DRA Consulting will become part of the broader PharmaLex Nordic region after the merger, making the Nordics the fourth largest market for PharmaLex.

Founded in 2002, DRA Consulting is one of the leading regulatory consulting companies in the Nordics and provides trusted end-to-end services to a diverse portfolio of more than 300 customers, offering intelligent solutions, across regulatory services, quality and manufacturing, pharmacovigilance and market access and reimbursement.

With headquarters in Vantaa, Finland, and employing more than 100 people, DRA Consulting combines international consultancy expertise with local knowledge and fluency in all Nordic languages. This eases the communication with regulatory authorities, aids follow-up and ensures the reliable management of national steps.

The merger also adds several state-of-the-art technology solutions to PharmaLex's growing digital platform, including robotics capabilities for pharmacovigilance, automation for writing sections of the CMC, and tools to harmonize some regulatory tasks.

"The merger is integral to helping us remain competitive in the future and to increasing our global market share. Together with PharmaLex we can achieve a stronger presence in the Nordic countries and globally giving our clients access to broader expertise in multiple markets.", said Kaija Korpiaho-Haga, CEO, partner and co-founder of DRA Consulting.

"The synergies between our two companies are strong, and our values and corporate cultures have a lot in common, thanks to the entrepreneurial spirit at both DRA and PharmaLex. Our flexibility and ability to respond quickly to client's requests aligns with a customer-centric approach at PharmaLex helping support a smooth merger between our teams. Ms. Korpiaho-Haga added.

“We are delighted to welcome the DRA team to the PharmaLex Group, and to have the opportunity to strengthen our Nordic footprint while also expanding our digital portfolio with the addition of DRA’s robotics and automation technologies,” said PharmaLex CEO Dr. Thomas Dobmeyer. “The merger builds on our long relationship with the owners of DRA as both PharmaLex Nordics and DRA Consulting have been part of the same European regulatory network (EuDRAcon) and have collaborated on multiple projects in the Nordic countries.”

-Ends-

About PharmaLex <Confidence beyond compliance>:

PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.

The PharmaLex Group now has over 2,800 employees, with 65 offices in 31 countries and more than 1,000 satisfied clients worldwide.

For further information, please contact:

Ms. Elizabeth Hunt; PharmaLex GmbH; Manager External Communications

elizabeth.hunt@pharmalex.com

+00 353 86 811 2319

Harrlachweg 6; 68163 Mannheim; Germany